

ZONAGEN INC  
Form 8-K  
September 03, 2004

**Table of Contents**

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**Current Report Filed Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

**Date of Report  
(Date of earliest event reported): September 2, 2004**

**ZONAGEN, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware  
(State or other jurisdiction of  
incorporation or organization)**

**0-21198  
(Commission File Number)**

**76-0233274  
(I.R.S. Employer Identification  
No.)**

**2408 Timberloch Place, Suite B-1  
The Woodlands, Texas 77380  
(Address of principal  
executive offices  
and zip code)**

**(281) 719-3400  
(Registrant's telephone  
number, including area  
code)**

---

---

---

**TABLE OF CONTENTS**

Item 8.01. Other Information

Item 9.01. Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

Press Release dated September 2, 2004

Presentation Slides

---

**Table of Contents**

**Item 8.01. Other Information**

Zonagen, Inc. announced today that Dr. Ronald Wiehle, the Company's Director of R&D, today delivered two presentations at the 12th International Congress of Endocrinology being held in Lisbon, Portugal from August 31 - September 4, 2004. The two presentations provided information for the previously released results of Zonagen's Phase I/II U.S. trial for Androxal in the treatment of men with low testosterone, as well as results from animal studies indicating the potential of Progenta in the treatment of breast cancer.

A copy of the Company's press release is attached hereto as Exhibit 99.1. A copy of the presentations given by Dr. Wiehle is attached hereto as Exhibit 99.2. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

**Item 9.01. Financial Statements and Exhibits**

c. Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated September 2, 2004.
99.2	Presentation Slides

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ZONAGEN, INC.**

Date: September 2, 2004.

By: /s/ Louis Ploth, Jr.

---

Louis Ploth, Jr.  
Vice President, Business Development and  
Chief Financial Officer

Table of Contents

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated September 2, 2004.
99.2	Presentation Slides